deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT00326625

Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)

A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of 40 mg Glatiramer Acetate Injection in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Sponsor: Teva Pharmaceutical Industries, Ltd.

Conditions Amyotrophic Lateral Sclerosis
Interventions 40 mg glatiramer acetate Placebo
Updated 11 times since 2017 Last updated: Aug 1, 2022 Started: Jul 27, 2006 Primary completion: Jun 17, 2008 Completion: Jun 17, 2008
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Amyotrophic Lateral Sclerosis and is currently completed. Teva Pharmaceutical Industries, Ltd. leads this study, which shows 11 recorded versions since 2006 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Mar 2018 · 13 months · monthly snapshotCompleted~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Nov 2021 · 10 months · monthly snapshotCompleted~Nov 2021 – ~Jan 2022 · 2 months · monthly snapshotCompleted~Jan 2022 – ~Sep 2022 · 8 months · monthly snapshotCompleted~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 10 months · monthly snapshotCompleted

Change History

11 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Sep 2022 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jan 2022 — Sep 2022 [monthly]

    Completed PHASE2

▶ Show 6 earlier versions

  1. Nov 2021 — Jan 2022 [monthly]

    Completed PHASE2

  2. Jan 2021 — Nov 2021 [monthly]

    Completed PHASE2

  3. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  4. Mar 2018 — Jun 2018 [monthly]

    Completed PHASE2

  5. Feb 2017 — Mar 2018 [monthly]

    Completed PHASE2

  6. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Jul 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Teva Pharmaceutical Industries, Ltd.
Data source: Teva Branded Pharmaceutical Products R&D, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations